Healthcare facilities need to provide the best possible care and outcomes for patients with COVID-19. To do this and truly protect patients not just from the risks associated with the initial COVID-19 infection but also with bacterial co-infections acquired within the healthcare system, hospitals should consider simultaneously incorporating broader testing for bacterial co-infections that can be acquired during a patient’s hospital stay. The solutions are readily available, FDA-cleared and easily integrated in the form of PCR, for lower respiratory specimens, LRT aspirate and BAL panels, and diagnostic technologies that quickly analyze pathogens and identify bacterial co-infections.
About the author: Oliver Schacht is the CEO of OpGen.Back to HCB News
